Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: Pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials

• Published in: Clinical therapeutics 2005-11, Vol.27 (11), p.1795-1805
• Main Authors: Lacourcière, Yves, Neutel, Joel M., Schumacher, Helmut
• Format: Article
• Language: English
• Subjects: ambulatory blood pressure monitoring; angiotensin II receptorblockade; Angiotensin II Type 1 Receptor Blockers - administration & dosage; Angiotensin II Type 1 Receptor Blockers - therapeutic use; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - therapeutic use; Antihypertensives; Benzimidazoles - administration & dosage; Benzimidazoles - therapeutic use; Benzoates - administration & dosage; Benzoates - therapeutic use; Biological and medical sciences; Blood Pressure; Cardiology; Diuretics - administration & dosage; Diuretics - therapeutic use; Drug Combinations; Drug dosages; Female; fixed-dose combination; Heart; Humans; hydrochlorothiazide; Hydrochlorothiazide - administration & dosage; Hydrochlorothiazide - therapeutic use; Hypertension; Hypertension - drug therapy; losartan; Losartan - administration & dosage; Losartan - therapeutic use; Male; Medical sciences; Middle Aged; Multicenter Studies as Topic; Pharmacists; Pharmacology. Drug treatments; Prevention; Prospective Studies; Public schools; Randomized Controlled Trials as Topic; Telmisartan
• ISSN: 0149-2918; 1879-114X
• DOI: 10.1016/j.clinthera.2005.11.014

High incidences of cardiovascularevents coincide with a surge in blood pressure (BP) that occurs in the early morning hours at the time of arousal. Thus, control of BP at this time of day, using oral fixed-dose combinations (FDCs) as required, is important in reducing cardiovascular risk in hypertensive patients. The aim of this analysis was to compare the annhypertensive efficacy in the early morning hours and tolerability of oral FDCs of telmisartan/hydrochlorothiazide (HCTZ) (40/12.5 mg [T40/H12.5] and 80/12.5 mg [T80/H12.5]) versus a low-dose FDC of losartan 50 mg/HCTZ 12.5 mg (L50/H12.5). Data from 2 similarly designed prospective, randomized, open-label, blinded-end point (PROBE) studies were pooled and analyzed. The studies were conducted at 72 centers across the United States, and 70 centers in Canada, Europe (9 countries), and the Philippines. Adult male and female patients with mild to moderate essential hypertension (24-hour mean ambulatory diastolic BP [DBP], ≥85 mm Hg; seated cuff DBP, 90–109 mm Hg) were enrolled. Patients were randomly assigned to receive T40/H12.5, L50/H12.5, or T80/H12.5, QD (morning) for 6 weeks. Antihypertensive efficacy was assessed using 24-hour ambulatory BP monitoring (ABPM) and cuff sphygmomanometry at trough, performed at baseline and on completion of active treatment. The primary end point was the reduction from baseline in mean ambulatory DBP over the last 6 hours of the dosing interval. Secondary end points included other ABPM- and clinic-derived changes in DBP and systolic BP (SBP), and control and response rates ( SBP response defined as 24-hour mean SBP